At a time of intensifying national polarization over critical race theory and affirmative action, leaders of cancer centers are faced with two challenges that appear to be diametrically at odds with each other
The cancer clinic at Tuba City, AZ, was a landmark from the day it opened its doors. It is, in fact, the only such clinic on any Indian reservation in the lower 48 states.
Every cancer center seeking to obtain (or keep) an NCI designation will soon have to present a plan for increasing the diversity of their faculty and workforce.
DEI Network founders: Let’s work together to increase diversity across all cancer centers in America
Christopher Li and Wendy Law, both of Fred Hutchinson Cancer Research Center, have a message for leaders of DEI programs in oncology.
Emergent public-private partnerships (PPPs) have risen to the occasion to streamline and coordinate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. With these monumental efforts have come important public discussions about equitable access and representation in clinical trials (CTs).
FDA watchers and clinical trialists in oncology may want to pay close attention to the agency’s latest plans to increase representation of traditionally marginalized populations in drug development.
There’s a cultural perception in drug development that enrolling a diverse, heterogeneous patient cohort can be “risky” for detecting drug effects—a perception that needs to go away, said Lola Fashoyin-Aje, associate director of the Science & Policy Program to Address Disparities at the FDA’s Oncology Center of Excellence and a deputy division director in the agency’s Office of Oncologic Diseases.
Drug manufacturers and researchers have a moral obligation to design clinical trials that adequately represent the target population for the investigational agent—and these medical products need to be safe and effective for everyone, leading clinical trial experts in oncology say.
The Association of American Cancer Institutes is designing two programs to address systemic underrepresentation of racial and ethnic minority physicians and scientists in leadership positions in oncology.
The vast majority of hospitals in the United States—up to 80%—treat patient populations that are disproportionately white, U.S. News & World Report said, unveiling a new suite of health equity measures earlier this week.
